BEI
CRSP icon

Benjamin Edwards Inc’s CRISPR Therapeutics CRSP Stock Holding History

Benjamin Edwards Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
54,488
-1,018
-2% -$53.7K 0.03% 462
2026
Q1 		$2.64M Buy
55,506
+870
+2% +$45.9K 0.03% 469
2025
Q4 		$2.87M Buy
54,636
+416
+0.8% +$24.9K 0.03% 420
2025
Q3 		$3.51M Sell
54,220
-3,540
-6% -$203K 0.04% 376
2025
Q2 		$2.81M Buy
57,760
+6,845
+13% +$265K 0.04% 392
2025
Q1 		$1.73M Buy
50,915
+5,853
+13% +$248K 0.02% 448
2024
Q4 		$1.77M Buy
45,062
+12,359
+38% +$584K 0.03% 466
2024
Q3 		$1.54M Buy
32,703
+32,465
+13,641% +$1.65M 0.02% 485
2024
Q2 		$13K Sell
238
-131
-36% -$7.58K ﹤0.01% 611
2024
Q1 		$25K Buy
369
+30
+9% +$2.15K 0.01% 552
2023
Q4 		$21K Sell
339
-165
-33% -$9.12K ﹤0.01% 535
2023
Q3 		$23K Buy
504
+13
+3% +$671 0.01% 525
2023
Q2 		$28K Sell
491
-67
-12% -$3.8K 0.01% 513
2023
Q1 		$25K Buy
558
+30
+6% +$1.46K 0.01% 520
2022
Q4 		$21K Buy
528
+107
+25% +$5.68K 0.01% 503
2022
Q3 		$28K Sell
421
-78
-16% -$5.65K 0.01% 473
2022
Q2 		$30K Buy
499
+19
+4% +$1.12K 0.01% 476
2022
Q1 		$30K Buy
480
+10
+2% +$628 0.01% 510
2021
Q4 		$36K Buy
470
+74
+19% +$6.46K 0.01% 453
2021
Q3 		$44K Sell
396
-14
-3% -$1.76K 0.03% 319
2021
Q2 		$66K Sell
410
-68
-14% -$8.27K 0.05% 249
2021
Q1 		$58K Sell
478
-67
-12% -$10.1K 0.04% 242
2020
Q4 		$83K Sell
545
-233
-30% -$27.5K 0.06% 203
2020
Q3 		$65K Buy
778
+48
+7% +$4.26K 0.05% 197
2020
Q2 		$54K Hold
730
– – 0.05% 194
2020
Q1 		$31K Buy
730
+109
+18% +$5.63K 0.03% 208
2019
Q4 		$38K Buy
621
+54
+10% +$2.95K 0.08% 139
2019
Q3 		$23K Buy
567
+21
+4% +$1K 0.05% 158
2019
Q2 		$26K Buy
546
+268
+96% +$10.7K 0.06% 149
2019
Q1 		$10K Buy
+278
New +$9.61K 0.05% 202

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Benjamin Edwards Inc's CRSP Position: Q2 2026 in Review

Benjamin Edwards Inc reduced its CRISPR Therapeutics (CRSP) stake by 1.8% in Q2 2026, selling an estimated $53.7K and leaving 54,488 shares worth $2.97M. The position accounts for 0.03% of the portfolio, ranked #462.

Benjamin Edwards Inc first reported a position in CRSP in Q1 2019 and has held it in 30 quarters since. The position peaked at $3.51M in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Benjamin Edwards Inc held 54,488 shares of CRISPR Therapeutics worth $2.97M as of Q2 2026.
  • Benjamin Edwards Inc sold 1,018 CRISPR Therapeutics shares in Q2 2026, an estimated $53.7K.
  • CRISPR Therapeutics made up 0.03% of Benjamin Edwards Inc's portfolio in Q2 2026, its #462 holding.
  • Benjamin Edwards Inc first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Benjamin Edwards Inc's CRISPR Therapeutics position peaked at $3.51M in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.